Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Progressive Corp (PGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Progressive Corp — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.36 (market cap $5.85B), while Progressive Corp trades at $218.73 (market cap $124.28B). The key difference: Progressive Corp is far larger — about 21.2× Iovance Biotherapeutics Inc. Common Stock's market cap, and Progressive Corp pays a 0.19% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Progressive Corp for 81 Days on average.
| IOVA | PGR | |
|---|---|---|
Market Cap | $5.85B | $124.28B |
Volume | 14,517,176 | 2,551,191 |
Sector | Health | Financials |
52-Week High | $14.82 | $242.16 |
52-Week Low | $1.81 | $190.40 |
Typical Hold Time | 0 Days | 81 Days |
Enterprise Value | $5.78B | $132.48B |
Dividend Yield | — | 0.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PGR trades at $218.73, up 3.15% today, with a bullish technical signal from moving averages and strong fundamentals including a 12.85% net income margin and 34.94% ROE. Revenue grew from $49.6B in 2022 to $87.6B in 2025, with net income surging to $11.3B. The company recently announced a $0.10 dividend payable in October 2026, and Q2 2026 earnings beat expectations.
The outlook is positive given robust earnings growth and analyst consensus price target of $222.23, though risks include intensifying competition in personal auto insurance and potential market volatility. Institutional interest remains strong with recent position increases by funds like QRG Capital Management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
